| 标题 |
Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:EClinicalMedicine 作者:Yuankai Shi; Keshu Zhou; Hui Zhou; Qin Yan; Hongmei Jing; et al 出版日期:2024-06-20 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)